



Docket No. 48977-DIV (71965)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Fukui et al.

SERIAL NO.: 10/007,790

GROUP: 1645

FILED: November 13, 2001

EXAMINER: S. Devi

FOR: MONOCLONAL ANTIBODY RECOGNIZING PHOSPHATIDYL-
INOSITOL-3,4,5-TRIPHOSPHATE

#13
Linda
5/15/03

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
Mail Stop Sequence

RECEIVED

MAY 14 2003

TECH CENTER 1600/2900

Sir:

RESPONSE TO OFFICE
LETTER UNDER 37 CFR §1.821(e)

Applicants submit herewith the following response to the Office Communication dated April 9, 2003.


The computer readable form in this application, U.S.S.N. 10/007,790, is identical with that filed in U.S.S.N. 09/257,069, filed February 24, 1999. In accordance with 37 CFR §1.821(e), please use the last-filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,

Christine C. O'Day

Christine C. O'Day (Reg. 38,256)
Edwards & Angell, LLP
P.O. Box 9169
Boston, MA 02209
Tel: 617-439-4444
Fax: 617-439-4170



1645
Docket No. 48977-DIV (71965)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Fukui et al.

SERIAL NO.: 10/007,790

GROUP: 1645

FILED: November 13, 2001

EXAMINER: S. Devi

FOR: MONOCLONAL ANTIBODY RECOGNIZING PHOSPHATIDYL-
INOSITOL-3,4,5-TRIPHOSPHATE

RECEIVED

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
Mail Stop Sequence

MAY 14 2003

TECH CENTER 1600/2900

Sir:

CERTIFICATE OF MAILING

I hereby certify that the following attached papers or fees

- (1) Response to Office Letter Under 37 CFR §1.821(e);
- (2) Acknowledgement postcard.

are being deposited with the United States Postal as "First Class Mail" on May 8, 2003 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Susan M. Dillon

Type or print name of person mailing paper

Susan M Dillon

Signature of person mailing paper

XEC/PRC/CCO 48977 DIV (71965)




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/007,790	11/13/2001	Yasuhisa Fukui	48977-DIV (71965)	1076

21874 7590 04/09/2003

EDWARDS & ANGELL, LLP
P.O. BOX 9169
BOSTON, MA 02209



EXAMINER

DEVI, SARVAMANGALA J N

ART UNIT PAPER NUMBER

1645

DATE MAILED: 04/09/2003


Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

MAY 14 2003

TECH CENTER 1600/2900

reg list due
Edwards & Angell LLP
Dike, Bronstein, Roberts & Cushman
101 Federal St, Boston, MA 02110
Date Rec'd 4/14/03
Docketed For 5/2/03-10/9/03
By RM
Approved _____



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
10/007,790	11/13/01	Fukui et al.	48977-DIV (71965)

EXAMINER	
S. Devi, Ph.D.	
ART UNIT	PAPER NUMBER
1645	11

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

- 1) This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicants must follow the format of the attached sample statement to request that the computer readable form filed in the parent application be used to create a computer readable form in this application.
- 2) APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD OF TIME FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R 1.821(g). Extensions of time may be obtained under the provisions of 37 C.F.R 1.136. In no case may an Applicant extend the period of reply beyond the SIX MONTH statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.
- 3) Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (703) 308-9347. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 7.45 a.m to 4.15 p.m. except one day each bi-week which would be disclosed on the Examiner's voice mail system.


If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's

supervisor, Lynette Smith, can be reached on (703) 308-3909. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

April, 2003


S. DEVI, PH.D.
PRIMARY EXAMINER



Application No.: 10/007,790

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212


PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RECEIVED
MAY 14 2003
TECH CENTER 1600/2900



Sample statement to request transfer of sequences

The following paragraph, or language having the same effect, can be used to invoke the procedures of 37 CFR section 1.821(e) in which an identical computer readable form from another application is used in a given application. The paragraph should be incorporated into a separate paper to be submitted in the given application.

The computer readable form in this application, 08/100,000, is identical with that filed in Application Number 07/999,999, filed March 1, 1998. In accordance with 37 CFR 1.821(e), please use the [first-filed, last-filed or only, whichever is applicable] computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is [included in the originally-filed specification of the instant application, included in a separately filed preliminary amendment for incorporation into the specification whichever is applicable].

RECEIVED
MAY 14 2003
TECH CENTER 1600/2900